ストックスクリーナーアプリを入手
366.20
8.15%
27.61
アフターアワーズ：
365.00
-1.20
-0.33%
Amgen Inc (AMGN) 最新ニュース
Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open - TechStock²
Amgen Earnings Call: Broad Growth Amid Manageable Risks - TipRanks
Amgen (AMGN) Surges on Q4 Earnings Beat, Leading Dow Gains - GuruFocus
US FDA Review Team Split On Amgen’s Tavneos Years Before Withdrawal Request - Citeline News & Insights
Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal? - Finviz
Amgen Seen Driving Long-Term Growth on R&D Pipeline, Oppenheimer Says - marketscreener.com
Amgen stock price jumps as earnings beat puts MariTide obesity bet back in focus - TechStock²
Amgen climbs 8% after upbeat earnings report - breakingthenews.net
Deep Dive Into Amgen Stock: Analyst Perspectives (14 Ratings) - Benzinga
BofA Securities reiterates Underperform rating on Amgen stock at $304 - Investing.com
Oncology Biosimilars Research and Global Forecast Report 2025-2030: Targeted Therapies, Emerging Market Expansion, and Novel Biosimilar Formulations Drive Growth - GlobeNewswire Inc.
Amgen Inc (AMGN) Stock Price Up 7.36% on Feb 4 - GuruFocus
Cantor Fitzgerald Raises Price Target for Amgen (AMGN) to $350 | - GuruFocus
Amgen thumbs-down on FDA’s ask, Tavneos sales continue - BioWorld MedTech
Cantor Fitzgerald Increases Amgen (NASDAQ:AMGN) Price Target to $350.00 - MarketBeat
Amgen’s FORTITUDE-301 Cancer Trial Completion: What Investors Should Watch in Bemarituzumab’s Next Act - TipRanks
Amgen Inc. (NASDAQ:AMGN) Q4 2025 earnings call transcript - MSN
Cantor Fitzgerald raises Amgen stock price target to $350 on strong earnings - Investing.com India
Why Amgen Stock Is Paying Off Big For Long-Term Investors - Forbes
Leerink Partners Adjusts Price Target on Amgen to $355 From $305, Maintains Market Perform Rating - marketscreener.com
AMGN's Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus - TradingView
Amgen (NASDAQ:AMGN) Sets New 1-Year High Following Strong Earnings - MarketBeat
Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan - BioPharma Dive
Amgen's Diversified Portfolio and Growing Cardiovascular Focus Support a Wide Moat - Morningstar
Amgen stock reaches all-time high of $353.74 By Investing.com - Investing.com Canada
Amgen stock reaches all-time high of $353.74 - Investing.com
Morgan Stanley Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
The Goldman Sachs Group Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price - MarketBeat
Royal Bank Of Canada Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
Leerink Partners Raises Amgen (AMGN) Price Target to $355 | AMGN Stock News - GuruFocus
Street View: Amgen banks on pipeline depth and long term weight-loss play - TradingView
Amgen (NASDAQ:AMGN) Price Target Raised to $355.00 - MarketBeat
Amgen Fell 4% Last Week. Here’s Where the Stock Could Head in 2026 - TIKR.com
Amgen Inc. (NASDAQ:AMGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge (AMGN) - Seeking Alpha
Amgen resists FDA request to pull rare disease drug Tavneos from the market - Fierce Pharma
Goldman Sachs Adjusts Price Target on Amgen to $415 From $403, Maintains Buy Rating - marketscreener.com
Amgen stock price target raised to $420 from $389 at TD Cowen - Investing.com
AMGN Q4 Deep Dive: Product Portfolio Expansion and Pipeline Progress Drive Outlook - Finviz
Amgen posts double-digit revenue and EPS growth for 2025 - The Pharma Letter
Amgen Drops Eczema Drug Pact As Investors Weigh R&D Focus And Valuation - simplywall.st
Amgen (NASDAQ:AMGN) Stock Unloaded Rep. David Taylor - MarketBeat
Rep. David Taylor Buys Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
A Decade of Rewards: $86 Bil From Amgen Stock - Trefis
Amgen CEO Teases 2026 As ‘Springboard Year’ After 14 Blockbusters And 18 Record Products - Stocktwits
Amgen’s Revenue Gains Outweigh News That FDA Wants Tavneos Pulled From Market - Citeline News & Insights
Amgen Inc (AMGN) Q4 2025 Earnings Call Highlights: Blockbuster Growth and Strategic Challenges - GuruFocus
Amgen Defends Tavneos Benefit-Risk Profile Following FDA Withdrawal Request - Medical Professionals Reference
Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating - TipRanks
US FDA Wants Tavneos Pulled From Market, Amgen Declines - Citeline News & Insights
Amgen (AMGN) Reports Strong 2025 Growth with Blockbuster Products - GuruFocus
Amgen Q4 results beat Street estimates, company says patients need weight-loss options By Reuters - Investing.com
Amgen (AMGN) Surpasses Q4 Expectations, Sets 2026 Guidance - GuruFocus
Amgen Q4 2025 slides: 10% revenue growth, robust pipeline advancement By Investing.com - Investing.com India
Amgen Beats Expectations as Top Drugs Boost Sales and Profit - Bloomberg.com
Amgen posts Q4 total revenue $9.87 bln vs IBES estimate $9.47 bln - marketscreener.com
Amgen (AMGN) Q4 2025 Earnings Call Transcript - AOL.com
Amgen Q4 2025 slides: 10% revenue growth, robust pipeline advancement - Investing.com
Amgen Q4 Earnings Call Highlights - MarketBeat
Amgen Inc (NASDAQ:AMGN) Beats Q4 2025 Estimates and Provides Strong 2026 Revenue Guidance - Chartmill
Here's What Key Metrics Tell Us About Amgen (AMGN) Q4 Earnings - Yahoo Finance
Amgen beats on both lines in Q4 and issues 2026 guidance (AMGN:NASDAQ) - Seeking Alpha
Amgen (AMGN) Surpasses Q4 Earnings Expectations with Strong Reve - GuruFocus
Amgen (AMGN) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance Singapore
Amgen : Highlights from Amgen's 2025 Fourth Quarter and Full Year Earnings Report - marketscreener.com
Amgen’s Revenue Climbs on Double-Digit Volume Boost - The Wall Street Journal
Highlights from Amgen's 2025 Fourth Quarter and Full Year Earnings Report - Amgen
Amgen (NASDAQ:AMGN) Issues Quarterly Earnings Results, Beats Expectations By $0.55 EPS - MarketBeat
Amgen Q4 Adjusted Earnings Fall, Revenue Rises; Issues Guidance - marketscreener.com
Amgen beats Q4 expectations with 9% revenue growth, issues strong 2026 guidance - Investing.com
Amgen (NASDAQ:AMGN) Reports Upbeat Q4 CY2025 - The Globe and Mail
6.18%
2.06%
大文字化:
|
ボリューム (24 時間):